

DISCUSSION

The present observation indicates that acitretin monotherapy is effective in the management of ACH. A further reduction of the dosage needed might be achieved by combining retinoids with classical topical antipsoriatics.

The LTB₄-induced intra-epidermal accumulation of PMN is a practical approach to study the migration of PMN through the skin. Already after 1 month of acitretin treatment at a dosage of 35 mg per day, the migration of these cells proved to be markedly inhibited. This observation further illustrates the effectiveness of relatively low doses of acitretin.

ACKNOWLEDGEMENTS

The authors wish to thank Professor B. M. Czarnetzki and Dr J. M. Geiger for helpful discussion. Ro 10-1670 was kindly

provided by Hoffmann-La Roche (Mijdrecht, The Netherlands, and Basle, Switzerland).

REFERENCES

1. Braun-Falco O, Berthold D, Ruzicka Th. Psoriasis pustulosa generalisata. Klassifikation, Klinik und Therapie. *Hautarzt* 1987; 38: 509-520.
2. Pearson LH, Allen BS, Smith JG. Acrodermatitis continua of Hallopeau: treatment with etretinate and review of relapsing pustular eruptions of the hands and feet. *J Am Acad Dermatol* 1984; 11: 755-762.
3. Camp R, Russell Jones R, Brain S, Woollard P, Greaves M. Production of intraepidermal microabscesses by topical application of leukotriene B₄. *J Invest Dermatol* 1984; 82: 202-204.
4. Van de Kerkhof PCM, Bauer FW, Maassen-de Grood RM. Methotrexate inhibits the leukotriene B₄ induced accumulation of polymorphonuclear leukocytes. *Br J Dermatol* 1985; 113: 251a-255a.
5. Lammers AM, van de Kerkhof PCM, Schalkwijk J, Mier PD. Elastase, a marker for neutrophils in skin infiltrates. *Br J Dermatol* 1986; 115: 181-186.

Treatment of Hyperhidrosis Manuum by Tap Water Iontophoresis

JENS CHRISTIAN DAHL and LENE GLENT-MADSEN

Department of Dermatology, Odense University Hospital, Odense, Denmark

In a randomised, double-blind, controlled clinical trial of the effect of treatment with tap water iontophoresis, 11 patients with palmar hyperhidrosis were treated actively on one hand and with placebo on the other. The patients' sweat production was 100% higher (median) than measured in control subjects of the same age and sex. Prior to iontophoresis, the patient's sweat production was the same on both hands but after treatment it was reduced significantly on the treated hand ($p < 0.01$) compared with the sweat production prior to treatment as well as with that of the untreated side. An 81% reduction (median) in sweating was found in 6 patients receiving maintenance treatment every second week. **Key words:** Antiperspirant; Sweating.

(Accepted December 20, 1988.)

Acta Derm Venereol (Stockh) 1989; 69: 346-348.

J. C. Dahl, Kastrup Skin Clinic, 168 Saltværksvej, DK-2770 Copenhagen, Denmark.

Emotional hyperhidrosis affects axillae, palms and soles. Tap water iontophoresis treatment of this condition has been known for more than fifty years but

has not been in common use until recently (1). A number of studies (1-5) have demonstrated an effect but a double-blind, controlled clinical study has never been carried out before.

The purpose of this study was to demonstrate the therapeutic effect of tap water iontophoresis treatment on emotional palmar hyperhidrosis.

MATERIAL AND METHODS

A randomised, double-blind, controlled clinical study of a group of patients with palmar hyperhidrosis treated actively on one hand and with placebo on the other.

A direct current (DC) generator (test model from Dermatron, 77 Tagensvej, DK-2200 Copenhagen) was used, securing a steady current in spite of alternating resistance. The generator produced 0-20 mA DC in two independent circuits with a maximum voltage of 30 V. A blind disconnection of one of the circuits was possible. Two aluminium plates measuring 12×31 cm and 13.5×21 cm were used as anode and cathode, respectively. The plates were fixed in cold tap water baths (6) and were covered with a plastic grill to protect the skin from burns. The palms were placed at the anodes and the soles at the cathodes so that the sole and palm of the same

side were part of the same circuit. The current of each treatment (7). The current of each treatment was broken double-blind randomisation with an alternate steps, of which half broke the other half the other circuit. The treatments of an individual primary randomisation. Each treatment (8). Initially, treatments were given to the patients reported good substance treatment was given with a high degree of acceptability to the patients and the patients' choice.

The study was performed on 11 patients with emotional palmar hyperhidrosis. The median age was 25 years (range 18-45). The hyperhidrosis was stopped two weeks before the study. The patients were compared with subjects of the same age and sex with hyperhidrosis, the sweat production on the hands (measured as described) increased by 100% (median; 1st and 166%, respectively). After 1 month of treatment the patients continued on maintenance treatment with moderate objective progress to insufficient subjective effect. The objective result of treatment was unknown reasons, respectively.

Immediately after the first treatment the patients were asked to try to determine when sweating was measured before and after 3 months of treatment. The hands were wiped dry the hands were under plastic gloves tied at the wrists. The emotional sweat stimulation through the gloves were removed and the current was stopped at 10^{-4} A.

Pratt's Rank Sum Test for paired data was used for statistical analysis (10). The test was performed in accordance with the Helsinki

RESULTS

The actively treated side of the hands and incorrectly by blinding of the patients.

A median current of 4 mA was administered 6 to 12 times before the patients reported a reduction in sweating. Pretreatment sweating was significantly higher ($p \gg 0.1$). Following the iontophoresis treatment the sweat production was reduced by 7% and 53% in the first and second quartiles were 7% and 53% compared with the untreated side.

side were part of the same circuit. Wounds and scratches, if any, were covered with a thin layer of petrolatum prior to treatment (7). The current of each circuit was set at precisely the maximum intensity which the patient was unable to feel. After randomisation with an envelope system one of the circuits was broken double-blind by a regulator with six different steps, of which half broke one of the circuits and the other half the other circuit. The same circuit was broken in all the treatments of an individual patient according to the primary randomisation. Each treatment lasted fifteen minutes (8). Initially, treatments were given 1 to 5 times a week until the patients reported good subjective effect. The maintenance treatment was given with the strongest current intensity acceptable to the patients and with intervals according to the patients' choice.

The study was performed on 8 female and 3 male patients with emotional palmar hyperhidrosis referred to the Department of Dermatology, Odense University Hospital. The median age was 25 years (range 18–44). All treatment of hyperhidrosis was stopped two weeks before iontophoresis. Compared with subjects of the same age and sex without subjective hyperhidrosis, the sweat production from the patients' hands (measured as described below) was found to be increased by 100% (median; 1st and 3rd quartiles were 54% and 166%, respectively). After the initial treatments, six patients continued on maintenance treatment. Three patients with moderate objective progress of treatment stopped owing to insufficient subjective effect. Two patients with improved objective result of treatment stopped owing to personal and unknown reasons, respectively.

Immediately after the first treatment the patients were asked to try to determine which side was actively treated. Sweating was measured before and after the initial treatment series and after 3 months of maintenance treatment: After being wiped dry the hands were inserted into cotton gloves under plastic gloves tied at the wrists. After ten minutes of emotional sweat stimulation through mathematical tests (9), the gloves were removed and the weight increase measured in $g \times 10^{-4}$.

Pratt's Rank Sum Test for paired data was applied for the statistical analysis (10). The test was designed and performed in accordance with the Helsinki Declaration II.

RESULTS

The actively treated side was given correctly by 6 patients and incorrectly by 5, which supports the true blinding of the patients.

A median current of 4 mA (range 2 mA–10 mA) was administered 6 to 12 times (median: 10 treatments) before the patients reported good subjective effect. Pretreatment sweating was equal on both sides ($p > 0.1$). Following the initial treatment series sweat production was reduced by 38% (median; 1st and 3rd quartiles were 7% and 53%, respectively). The fall in sweat production was significant ($p < 0.01$). Compared with the untreated side, the sweat production

was reduced by 32% (median; 1st and 3rd quartiles were 17% and 56%, respectively), which was also significant ($p < 0.01$).

All maintenance treated patients preferred treatment every second week. A median current of 10 mA (range 7 mA–14 mA) was applied. After 3 months of maintenance treatment sweating was found to be reduced by 81% (median; 1st and 3rd quartiles were 60% and 95%, respectively, $p < 0.05$).

No side effects were observed in any patient.

DISCUSSION

The study showed none of the side-effects described in the past as soreness, erythema, vesicles, and even bullae and burns (4, 7, 11). The highest current intensity tolerated without side-effects was 0.3 mA/cm²–0.5 mA/cm² (8, 11). Owing to the lack of protection between electrodes and hands, a patient who came in too close contact with the electrodes at a later treatment (current intensity 14 mA), developed multiple deep bullae (12). The determining factor thus seems to be the direct contact with the electrodes in small areas which increases the applied current per cm² uncontrollably.

The number of treatments necessary for good subjective effect depends on the frequency of the treatments given, which is variably indicated in the literature. The median number of 10 treatments in our study was comparable with the number of treatments in other recent studies (2, 4). However, the applied median current of 10 mA during the maintenance treatment was less than the current used by others (2, 4). This may be due to the application of different types of electrodes. The median current of 4 mA used in the initial double-blind study was not optimal as the sweat reduction was further increased from 38% to 81% with an increase in current to the maximum tolerable value of 10 mA. The patients' preferred treatment interval of two weeks as well as the demonstrated sweat reduction of 81% were comparable with the results in other studies (2, 4). However, the effect of treatment may be less if other types of iontophoretic devices are used (13, 14). Local treatment with aluminium chloride hexahydrate in absolute ethanol has been applied to hyperhidrosis manuum reducing sweating by 66% (15). Tap water iontophoresis thus seems to be the most effective local treatment of hyperhidrosis manuum.

REFERENCES

1. Sloan JB, Soltani K. Iontophoresis in dermatology. *J Am Acad Dermatol* 1986; 15: 671-684.
2. Hölzle E, Pauli M, Braun-Falco O. Leitungswasser-Iontophorese zur Behandlung von Hyperhidrosis manuum et pedum. *Hautarzt* 1984; 35: 142-147.
3. Boumann HD, Lentzer EMG. The treatment of hyperhidrosis of hands and feet with constant current. *Am J Phys Med* 1952; 31: 158-169.
4. Hölzle E, Alberti N. Long-term efficacy and side effects of tap water iontophoresis of palmo-plantar hyperhidrosis—the usefulness of home therapy. *Dermatologica* 1987; 175: 126-135.
5. Stolman LP. Treatment of excess sweating of the palms by iontophoresis. *Arch Dermatol* 1987; 123: 893-896.
6. Zankel HT. Effect of physical modalities upon Ra I³¹ iontophoresis. *Arch Phys Med Rehabil* 1963; 44: 93-97.
7. Levit F. Treatment of hyperhidrosis by tap water iontophoresis. *Cutis* 1980; 26: 192-194.
8. Shrivastava SN, Singh G. Tap water iontophoresis in palmo-plantar hyperhidrosis. *Br J Dermatol* 1977; 96: 189-195.
9. Quatralo RP, Stoner KL, Felger CB. A method for the study of emotional sweating. *J Soc Cosmet Chem* 1977; 28: 91-101.
10. Rahe AJ. Tables of critical values for the Pratt matched pair signed rank statistic. *J Am Stat Assoc* 1974; 69: 368-373.
11. Zlotogorski A, Shafran A. Iontophoresis in dermatology. *J Am Acad Dermatol* 1987; 17: 690.
12. Dahl JC. Iontoforesebehandling af emotional hyperhidrose. *Månedsskrift for praktisk lægegering* (in press).
13. Akins DL, Meisenheimer JL, Dobson RL. Efficacy of the Drionic unit in the treatment of hyperhidrosis. *J Am Acad Dermatol* 1987; 16: 828-832.
14. Hölzle E, Ruzicka T. Treatment of hyperhidrosis by a battery-operated iontophoretic device. *Dermatologica* 1986; 172: 41-47.
15. Jensen O, Karlsmark T. Palmo-plantar hyperhidrosis. Treatment with alcoholic solution of aluminium chloride hexahydrate: a simple method of transpiration measurement. *Dermatologica* 1980; 161: 133-135.

Treatment of Scabies with Permethrin Versus Lindane and Benzyl Benzoate

UWE-FRITHJOF HAUSTEIN and BARBARA HLAWA

Department of Dermatology, School of Medicine, Karl Marx University, Leipzig, GDR

This open clinical study was designed to evaluate and compare the efficacy and side effects of lindane (1% and 0.3%), benzyl benzoate (20% and 10%) and permethrin (5% and 2.5%) after two, three, and one application at bedtime, in the treatment of scabies in 114 adults and 80 children aged between 0 and 5 years. Treatment failures were registered after lindane in 3 adults and 2 children, whereas benzyl benzoate and permethrin cured all patients as assessed after a 3-week follow-up. The number of irritations and post-scabious eczematous reactions was increased after benzyl benzoate treatment. Permethrin proved to be very reliable and exhibited few side effects when applied once at bedtime. Because of the percutaneous absorption and neurotoxicity of lindane, the application of permethrin can be recommended as a useful alternative in premature infants and small children, patients with seizures and neurological complications, in cases of therapeutic failure with lindane the treatment needs to be repeated, in scabies crustosa, as well as in children, pregnant women and nursing mothers.

(Accepted January 31, 1989.)

Acta Derm Venereol (Stockh) 1989; 69: 348-351.

Acta Derm Venereol (Stockh) 69

U.-F. Haustein, Department of Dermatology, School of Medicine, Karl Marx University, Liebigstr. 21, Leipzig, GDR-7010.

For 30 to 40 years the insecticide lindane (γ -hexachlorocyclohexane) has been known to be effective and reliable in the treatment of scabies (1), even in children, pregnant women and nursing mothers (2). It is neither a mutagen nor a teratogen. Lindane has a LD₅₀ of 90 mg/kg in mice and exerts neurotoxic effects, especially upon the central nervous system, due to its lipophilic properties (3). In recent years, side-effects of lindane such as irritability, nervousness, apprehension, insomnia, seizures, apathy, coma, respiratory arrest and death (4) were reported repeatedly in isolated cases of small children (5, 6) and patients with neurological disorders. In most cases this was attributed to abuse, overuse or treatment failure, or even to accidental ingestion. On the other hand small amounts of epicutaneously applied lindane (in particular on wet, inflamed or excoriated skin in small

children) are known to lead to an increase in peak after 6 h, and

Usually, adults with skin at bedtime on children we have moderate. Lindane (HCH) and its concentration 0.3%, or else the surface are treated (split application).

The purpose of this study was to compare lindane with permethrin in a clinical trial. Less than 10% of patients were treated with lindane (10%) and discussed here. Benzyl benzoate, also known as benzyl benzoate, has been recommended in combination with lindane in liquid form with strong irritative effects on the excoriated skin during successive nights (1). The combination of benzyl benzoate with lindane is bactericidal, fungicidal and has a low toxicity (LD₅₀ mice) than lindane (13) and is practically non-toxic (<2%). It is metabolized in the skin and excreted in the urine and does not have the cosmetic side effects of lindane, even in a 25:75 ratio.

Permethrin (3-(4-chlorophenyl)-2,2-dimethylbutylate) occurs as a natural product of *Chrysanthemum* and is highly stable and non-toxic. It is inherently more toxic (LD₅₀ mice) than lindane (13) and is practically non-toxic (<2%). It is metabolized in the skin and excreted in the urine and does not have the cosmetic side effects of lindane, even in a 25:75 ratio.

In the following study, the efficacy of permethrin and benzyl benzoate and per-

MATERIAL AND METHODS

Adults and children were divided into different groups ($n = 10$) with lower concentrations were applied over 1 and 3 consecutive nights.

The formulations of lindane (HCH ointment) were: 0.2% (Ung. c. 0.2%) and 0.3% (Ung. c. 0.3%).